Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection
Wissam El-Hage1, Simon A Surguladze21Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; 2Institute of Psychiatry, King’s College London, UKAbstract: Bipolar disorder is a life-lon...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9438f72e3cf64499a36e8bf6a82f9197 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9438f72e3cf64499a36e8bf6a82f9197 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9438f72e3cf64499a36e8bf6a82f91972021-12-02T04:39:52ZEmerging treatments in the management of bipolar disorder – focus on risperidone long acting injection1176-63281178-2021https://doaj.org/article/9438f72e3cf64499a36e8bf6a82f91972010-07-01T00:00:00Zhttp://www.dovepress.com/emerging-treatments-in-the-management-of-bipolar-disorder-ndash-focus--a4921https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Wissam El-Hage1, Simon A Surguladze21Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; 2Institute of Psychiatry, King’s College London, UKAbstract: Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. ­Risperidone long acting injection (RLAI) as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA) in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting injections will also be discussed.Keywords: second generation, antipsychotics, patient attitudes, lithium, valproate, monotherapy Wissam El-HageSimon A SurguladzeDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 455-464 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wissam El-Hage Simon A Surguladze Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection |
| description |
Wissam El-Hage1, Simon A Surguladze21Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; 2Institute of Psychiatry, King’s College London, UKAbstract: Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. ­Risperidone long acting injection (RLAI) as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA) in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting injections will also be discussed.Keywords: second generation, antipsychotics, patient attitudes, lithium, valproate, monotherapy |
| format |
article |
| author |
Wissam El-Hage Simon A Surguladze |
| author_facet |
Wissam El-Hage Simon A Surguladze |
| author_sort |
Wissam El-Hage |
| title |
Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection |
| title_short |
Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection |
| title_full |
Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection |
| title_fullStr |
Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection |
| title_full_unstemmed |
Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection |
| title_sort |
emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/9438f72e3cf64499a36e8bf6a82f9197 |
| work_keys_str_mv |
AT wissamelhage emergingtreatmentsinthemanagementofbipolardisorderampndashfocusonrisperidonelongactinginjection AT simonasurguladze emergingtreatmentsinthemanagementofbipolardisorderampndashfocusonrisperidonelongactinginjection |
| _version_ |
1718401137192730624 |